How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with ALK-rearranged lung cancers. The echinoderm microtubule-associated protein-like (EML)-ALK translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Bing, Nagasaka, Misako, Zhu, Viola W., Ou, Sai-Hong Ignatius, Soo, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815371/
https://www.ncbi.nlm.nih.gov/pubmed/33489815
http://dx.doi.org/10.21037/tlcr-20-331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815371/
https://www.ncbi.nlm.nih.gov/pubmed/33489815
http://dx.doi.org/10.21037/tlcr-20-331

Ejemplares similares